Cytek Biosciences (CTKB) UBS Global Healthcare Conference 2024 summary

Business overview and strategy

• Operates on four business pillars: instruments, applications, bioinformatics, and clinical, with a focus on immune cell analysis and recurring revenue from reagents.

• Over 2,800 instruments deployed in 70+ countries, serving 1,500+ customers and cited in 2,000+ peer-reviewed papers.

• Revenue exceeds $200 million in the last twelve months, with adjusted EBITDA over $20 million and $278 million in cash; ongoing share buybacks.

• Revenue split: ~50% U.S., 33% Europe, 20% APAC/ROW; customer base is 40% academic, 60% commercial (pharma, biotech, CRO, hospitals).

• Instruments account for 70% of revenue, with reagents, software, and services making up the remaining 30%.

Product innovation and market positioning

• Full Spectrum Profiling technology underpins instruments, enabling high-dimensional cell analysis and harmonization for pharma and CROs.

• Product portfolio includes Aurora, Northern Lights, Orion, Amnis, Guava, and Athena, each targeting specific market segments and applications.

• Focuses on select reagents for spectral data analysis, especially for pharma customers, rather than broad catalog offerings.

• Cytek Cloud bioinformatics platform automates panel design and data management, now with 12,000+ users.

• Imaging flow cytometry (ImageStream) offers single-cell microscopy, supporting advanced research and clinical validation, such as gene therapy efficacy.

Financial performance and operational efficiency

• Maintains profitability and positive cash flow, with a gross margin target of 60% and 20% of revenue invested in R&D.

• Pursues operational efficiency and cost-effectiveness to drive both top and bottom line growth.

• Growth strategy includes M&A, with four acquisitions to date expanding technology, recurring revenue, and service capabilities.